NFKB1 and COVID-19: Possible adverse effects of NF-κB inhibition in Tregs include increased risk of autoimmunity and impaired tissue repair, potentially slowing recovery in COVID-19 patients or leading to long-term damage in affected tissues, such as the lungs.